ISRCTN02847428已完成未知
To evaluate the efficacy, safety and tolerability of Hilterapia® (High Intensity Laser Therapy) in the chronic articular inflammatory processes in haemophilic adult patients: an interventional pilot multicentre study
Baxter (Italy)0 个研究点目标入组 11 人开始时间: 2011年9月13日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 11
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Adult subjects with haemophilia A of any severity with or not suppressant
- •2. Age more than or equal to 18 years
- •3. Subjects who have been previously diagnosed with a chronic articular inflammatory process or hematoma
- •4. Subjects who have signed an informed written consent
排除标准
- •Subjects with under way bleeding
研究者
相似试验
已完成
3 期
Clinical study on Abhraloha in iron deficiency AnemiaCTRI/2019/01/017303Shree Dhootapapeshwar Limited57
已完成
1 期
An Open Label Study, to Evaluate Safety, Tolerability, and Efficacy in Male and Female with Androgenetic Alopecia Treated with HMI-115 over a 24-Week Treatment PeriodAndrogenetic AlopeciaACTRN12622000680763Hope Medicine (Nanjing) Co., Ltd16
进行中（未招募）
1 期
Evaluation of the efficacy, safety and tolerability of alisporivir for the treatment of hospitalised patients with infections due to SARS-CoV-2 (COVID-19).The study population will consist of adults (18-80 years old) hospitalised for =48 hours prior to randomisation with a diagnosis of COVID-19 based on symptoms onset and SARS-CoV-2 RT-PCR test positive from nasopharyngeal swab. Patients with ARDS or patients requiring mechanical ventilation at screening or randomisation will be excludedMedDRA version: 23.0Level: PTClassification code 10051905Term: Coronavirus infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2020-002295-13-FRAssistance Publique - Hôpitaux Paris100
进行中（未招募）
1 期
Evaluation of the therapeutic potential of a low-dose therapy with the interleukin-2 analogue Aldesleukin (Proleukin®) in the treatment of systemic lupus erythematosus.Patients with systemic lupus erythematosus (SLE) and increased disease activity refractory to standard therapies.MedDRA version: 18.0Level: PTClassification code 10042945Term: Systemic lupus erythematosusSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersMedDRA version: 18.0Level: PTClassification code 10067657Term: Systemic lupus erythematosus disease activity index increasedSystem Organ Class: 10022891 - InvestigationsEUCTR2013-001599-40-DECharité - Universitätsmedizin Berlin12
已完成
1 期
Evaluation of the safety, tolerability, efficacy and immunological responses of the interleukin-2 analogue Aldesleukin (Proleukin®) in the treatment of systemic lupus erythematosus as prototypic autoimmune disease (PRO-IMMUN)M32.1Systemic lupus erythematosus with organ or system involvementDRKS00004858Charité - Universitätsmedizin Berlin10